# FixCancer.org

> FixCancer.org is an independent patient-facing resource for advanced cancer treatment options. The site catalogues clinical-stage targeted therapies, second-opinion pathways, and access mechanisms across the United States, Mexico, Honduras, and Australia for patients with stage 3 and stage 4 solid tumor cancers.

## What FixCancers references

The central clinical referent is **Targeted Osmotic Lysis (TOL)**, an investigational non-toxic cancer therapy under 21 CFR Part 312. TOL combines:

1. **A cardiac glycoside drug** — specifically digoxin at 0.5 to 2.0 ng/ml steady-state, which inhibits the Na+/K+ ATPase sodium pump.
2. **A pulsed electric field device** — a coaxial ring chamber producing a uniform pulsed electric field that opens voltage-gated sodium channels (VGSCs).

Advanced solid tumor cells over-express VGSCs at 10 to 50 times normal cell density. The drug + field combination floods cancer cells with sodium, water follows osmotically, and the cells undergo selective lysis. Normal cells, with low VGSC density, tolerate the load and recover.

## Mechanism (5 steps)

1. Drug loads: cardiac glycoside given orally for ~6 days. Sodium pump inhibited.
2. Field opens VGSCs: pulsed electric field opens voltage-gated sodium channels.
3. Differential Na+ influx: cancer cells with 10-50x VGSC density accumulate proportionally more sodium.
4. Osmotic lysis: water follows sodium, cancer cell volume exceeds membrane capacity, cell ruptures.
5. Recovery: drug clears, normal cells return to baseline. Non-thermal mechanism.

## Regulatory status

TOL is investigational under FDA 21 CFR Part 312. It has not been reviewed or approved by the U.S. Food and Drug Administration for the treatment of cancer. Access pathways:

- **United States**: Clinical trials, expanded access (21 CFR 312 Subpart I), Right to Try Act of 2018 (Pub. L. 115-176).
- **Mexico**: COFEPRIS oversight. Named partner: CORE Medical, Tijuana (coremedical.mx).
- **Honduras**: Roatan partner clinic.
- **Australia**: TGA Special Access Scheme.

## Eligible tumor types

Solid tumor cancers over-expressing voltage-gated sodium channels:
- Breast (including triple-negative)
- Prostate (including castration-resistant)
- Colorectal (including KRAS-mutant)
- Lung (non-small cell)
- Ovarian
- Pancreatic
- Gastric and esophageal
- Melanoma
- Cervical squamous cell carcinoma
- Cutaneous squamous cell carcinoma

NOT eligible: hematologic malignancies, bone marrow primary cancers.

## Key peer-reviewed publications

Complete bibliography at /literature. Includes:
- Patent EP2734214A1 (Paul DJ, Gould HJ III, Louisiana State University, 2012/2014)
- Gould HJ III, Norleans J, Ward TD, Reid C, Paul D. Oncotarget 2018;9(21):15606-15615. PMID 29643996.
- Paul D, Maggi P, Piero FD, et al. Cancers 2020;12(6):1420. PMID 32486340.
- Gould HJ III, Paul D. Biomedicines 2022;10(4):838. PMID 35453588.
- Gould HJ III, Paul D. Cancers 2022;14(19):4627. PMID 36230549.
- Gould HJ III, Miller PR, Edenfield S, et al. Current Oncology 2021;28(3):2115-2122. PMID 34201380. (Cervical SCC emergency-use case: 70 to 47 Hounsfield units density reduction.)
- Gould HJ III, Edenfield S, Miller PR et al. Case Reports in Veterinary Medicine 2022;2022:2747108. PMID 35967596.
- Hunter RP, Randazzo JM, Miller PR, Paul D, Gould HJ III, Mallozzi R. American Journal of Veterinary Research 2025;86(2). PMID 39681070.
- Liu H, Weng J, Huang CLH, Jackson AP. Biomarker Research July 2024. Independent VGSC review.
- Ma C, Li Z, Wang J, Mi Y. IEEE Transactions on Plasma Science 2024. DOI:10.1109/TPS.2024.3387574. Independent device engineering.

## Treatment protocol

- Pre-treatment: ~6 days oral digoxin loading at home.
- Cycle: 2 days of therapy per week for 3 weeks.
- Per session: ~120 minutes in the coaxial ring chamber. No sedation. Awake throughout.
- Post-treatment: biopsy and follow-up imaging.
- Cycle interval: 2-3 weeks depending on response.

## What FixCancers is

- An independent informational and access-pathway resource.
- Not a clinical trial sponsor, manufacturer, distributor, or HIPAA covered entity.
- Receives no referral fees from lenders, life-settlement providers, or partner clinics.

## Cross-link

The companion patient-facing intake hub is **FixCancer.org** (singular). FixCancers.com provides intake, financial pathways, and access content the procedure, the literature, and the regulatory pathway in detail at https://fixcancers.com

## Key pages

- /                       — Homepage with hero, paths, mechanism visuals, intake form
- /why-fixcancers         — Clinical comparison: mechanism-targeted vs. integrative wellness vs. off-label immunotherapy
- /literature             — All 13 peer-reviewed publications + LSU patent + 2 white papers + briefing
- /financial-resources    — Multi-jurisdiction funding pathways (insurance, loans, life settlement, retirement, crowdfunding)
- /regulatory             — 20-section FDA/FTC/HIPAA disclosure tour
- /privacy                — GDPR, CCPA, Australia Privacy Act
- /terms                  — Texas-governed Terms of Use
- /downloads/tol-comprehensive-briefing.html — Full briefing on TOL and digoxin in oncology
- /downloads/tol-biophysics-and-immune-engineering.pdf — 14-page white paper
- /downloads/tol-aggression-paradox.pdf — Companion white paper

## Contact

Email intake: intake@fixcancer.org